Stifel Nicolaus Has Lowered Expectations for Alto Neuroscience (NYSE:ANRO) Stock Price

Alto Neuroscience (NYSE:ANRO - Get Free Report) had its price target dropped by Stifel Nicolaus from $32.00 to $10.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Stifel Nicolaus' price objective indicates a potential upside of 120.75% from the company's previous close.

A number of other research firms also recently weighed in on ANRO. William Blair restated an "outperform" rating on shares of Alto Neuroscience in a report on Tuesday, September 10th. Rodman & Renshaw downgraded shares of Alto Neuroscience from a "buy" rating to a "neutral" rating in a report on Wednesday, October 23rd. Wedbush downgraded shares of Alto Neuroscience from an "outperform" rating to a "neutral" rating and dropped their target price for the stock from $29.00 to $4.00 in a report on Wednesday, October 23rd. RODMAN&RENSHAW downgraded shares of Alto Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 23rd. Finally, Robert W. Baird dropped their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set an "outperform" rating on the stock in a report on Wednesday, October 23rd. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $20.00.

Alto Neuroscience Trading Up 0.7 %

ANRO stock traded up $0.03 during midday trading on Wednesday, reaching $4.53. The company had a trading volume of 591,041 shares, compared to its average volume of 374,697. The company has a 50 day moving average of $10.20 and a two-hundred day moving average of $11.50. The company has a quick ratio of 19.85, a current ratio of 19.85 and a debt-to-equity ratio of 0.04. Alto Neuroscience has a 1 year low of $3.61 and a 1 year high of $24.00.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.67) by $0.05. As a group, equities analysts expect that Alto Neuroscience will post -2.63 EPS for the current fiscal year.

Institutional Trading of Alto Neuroscience

Several institutional investors have recently made changes to their positions in ANRO. Vanguard Group Inc. acquired a new stake in shares of Alto Neuroscience during the 1st quarter valued at about $8,233,000. Price T Rowe Associates Inc. MD acquired a new stake in shares of Alto Neuroscience during the 1st quarter valued at about $9,788,000. AWM Investment Company Inc. acquired a new stake in shares of Alto Neuroscience during the 1st quarter valued at about $4,592,000. Zimmer Partners LP bought a new position in Alto Neuroscience during the 1st quarter valued at about $1,151,000. Finally, Artal Group S.A. bought a new position in Alto Neuroscience during the 1st quarter valued at about $5,372,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.